August's IPO Market Opens Hot: Biotech Wave, SpaceX Lockup, and Switch's $50B Filing

The biotech window is wide open — and issuers are pushing through it

The first week of August 2026 delivered the busiest stretch for biotech IPOs since mid-April, with four clinical-stage companies all upsizing their offerings at pricing. Together, Braveheart Bio (BRVE), Latigo Biotherapeutics (LTGO), Attovia Therapeutics (ATTO), and BlossomHill Therapeutics (BLSM) raised $1.17 billion on Nasdaq.^[1]

Every one of these deals was upsized — the underwriting signal that demand outpaced the original share count. Braveheart Bio raised $383 million at a $1.6 billion market cap, pricing above its range, and finished its first week up 67%. Latigo Biotherapeutics raised $346 million at the top of its range, pricing at a $1.3 billion market cap. Attovia Therapeutics raised $289 million at the high end of its range. BlossomHill Therapeutics raised $150 million at the midpoint.^[2]

The backdrop explains the confidence. U.S. biotech and pharmaceutical sector IPOs produced a weighted average return of 55 percent through late July, according to Bloomberg data cited by IPOScoop.^[3] BioCentury reports that twenty biotechs have now raised a combined $6.9 billion in Nasdaq IPOs this year, with fourteen posting first-day gains.^[1] Earlier 2026 biotech listings have been the pace-setters: Veradermics (MANE) closed at $101.89 on August 3 — nearly six times its $17.00 IPO price — and Hemab Therapeutics (COAG) more than doubled its $18.00 offer price to $45.00.^[3]

The deals span the clinical pipeline from Phase 1 through Phase 3-ready, suggesting the market is not discriminating narrowly by stage. Braveheart’s lead candidate BHB-1893, a next-generation oral cardiac myosin inhibitor for hypertrophic cardiomyopathy, is heading into global Phase 3 trials in 2H26.^[2] Latigo’s LTG-001, an oral Nav1.8 inhibitor for acute pain, has Phase 3 trials planned for 2H26 with topline results expected in 2H27.^[2] Attovia’s ATTO-1310 targets IL-31 for chronic pruritus, with a Phase 2 trial planned for 1H27.^[2] BlossomHill’s BH-30643 is in a Phase 1/2 trial for EGFR-mutant NSCLC, with an FDA end-of-Phase 1 meeting targeted for 4Q26.^[2]

Source: Renaissance Capital weekly recap, Aug. 7, 2026. Returns as of Aug. 7 close.}

The performance spread is wide. Braveheart’s 67% first-week gain dwarfs BlossomHill’s flat finish and Latigo’s 1% drift, which suggests the market is rewarding Phase 3-ready assets with large addressable populations (cardiac myosin inhibition, non-opioid pain) more generously than earlier-stage or more niche plays. The base rate for biotech IPOs this year is strong, but dispersion within the cohort is real.

SpaceX lockup: 911 million shares unlocked, and the stock went up

The most talked-about lockup expiration in IPO history arrived on Thursday, August 6, when 911 million SpaceX (SPCX) shares became eligible for sale — more than doubling the company’s public float of roughly 639 million shares.^[4][5]

The stock rose 6.1% to close at $114.92.^[6] That counterintuitive result came after shares had fallen nearly 14% the prior day and had already dropped 49% from their June high of $225 — a rout that wiped out hundreds of billions in market value and pushed the stock below its $135 IPO price.^[6]

Morgan Stanley analyst Adam Jonas called the lockup expiration an opportunity to buy the stock cheaply, reiterating a $300 price target by mid-2027.^[6] SpaceX reported Q2 results earlier in the week: a 92% revenue jump to $7.8 billion, though the company posted a $541 million net loss and sharply higher R&D and AI infrastructure spending.^[6] The company said it is on track for $100 billion in annualized revenue by year-end.^[4]

What makes SpaceX’s lockup unusual is its staggered structure. Rather than releasing all restricted shares on a single day, the banks scheduled releases over nearly a year. Thursday’s unlock frees 911 million shares; by mid-2027, an additional 12.9 billion shares will be freed.^[4] CEO Elon Musk’s approximately 42% stake remains locked until one year after the IPO.^[4] Executive officers face longer lockups that generally do not begin expiring until after Q4 results.^[4]

The key question is not how many shares were unlocked but how many actually sell. Brokers reported heavy interest from pre-IPO investors eager to exit and redeploy into other private-market names like Anthropic, OpenAI, and Anduril.^[4] But at least one wealth advisor with SpaceX insider contacts said his clients are “long-term believers” who are not rushing to sell.^[4] The first lockup window passed without a visible flood — but nine more months of staggered releases remain, and the float could ultimately triple if a price-based early-release provision triggers.^[4]

Switch confidentially files: the next data-center mega-IPO

On Friday, August 7, Bloomberg reported that Switch Inc., the Las Vegas-based data-center operator, filed confidentially for a U.S. IPO.^[7] The company is working with Bank of America, Citigroup, Goldman Sachs, JPMorgan, and Morgan Stanley, and could seek a valuation approaching $50 billion including debt.^[8] Some reports cited figures as high as $80 billion including debt, with the offering potentially raising up to $10 billion as soon as Q4 2026.^[9]

Switch was taken private in 2022 by DigitalBridge Group and IFM Investors in an $11 billion transaction.^[8] DigitalBridge has since agreed to be acquired by SoftBank Group.^[8] As part of the pre-IPO capital alignment, Andreessen Horowitz’s Ben Horowitz is joining Switch’s board, with a16z leading a strategic investment round.^[8]

Switch’s filing extends a pattern of data-center operators tapping public markets for AI-infrastructure capital. Blackstone Digital Infrastructure Trust raised $2 billion in a May IPO, and Brookfield-backed Csquare raised $1.21 billion last month.^[8] The sector is racing to match surging enterprise demand for AI compute — and equity markets, at least for now, are willing to fund it.

The broader tape

Beyond this week’s headline deals, the new-issuance pipeline is broadening:

• Jersey Mike’s Subs (JMKE) raised $1.0 billion in a Blackstone-backed restaurant IPO, pricing 43.5 million shares at $23 — but 68% of the deal was secondary, and shares closed down about 6% on the first day.^[10]
• River City Bank (RCBC) raised $122 million at a $637 million market cap, pricing below range but finishing the week up 4%.^[2]
• Five SPACs also priced during the week, and eight more filed initial S-1s.^[2]
• On the buyback side, MetLife (MET) authorized a new $3 billion repurchase program on August 5,^[11] Deutsche Telekom increased its 2026 buyback by up to €3 billion,^[11] BASF began a new €1.0 billion buyback program in August,^[11] and ING continued executing its €1.0 billion program.^[11]

The Renaissance IPO Index was up 18.8% year-to-date as of August 6, outpacing the S&P 500’s 13.4% gain.^[2] The Renaissance International IPO Index was up 40.0% year-to-date.^[2]

What to watch next

1. SpaceX staggered lockups. The August 6 release was the first of several. Each subsequent tranche will test whether early investors hold or sell. If the price-based early-release provision triggers — which could happen if the stock trades above certain thresholds — the float could triple, not merely double.^[4]

2. Switch IPO timeline. A confidential filing means no public S-1 yet. Watch for a public filing in the coming weeks, which would reveal financials, deal size, and timing. A Q4 2026 listing window would put Switch in the same queue as other late-2026 large-cap tech offerings.

3. Biotech IPO momentum sustainability. Four upsized deals in one week is a strong signal, but the dispersion in aftermarket performance (Braveheart +67%, BlossomHill flat) suggests the market is not indiscriminate. The next batch of biotech filings will indicate whether the window is widening or whether latecomers will face a colder reception.

4. Lockup releases for other 2026 IPOs. Renaissance Capital noted six IPO lockup releases in the coming week alone.^[1] As the 2026 IPO class ages into lockup-expiry territory, supply pressure will be a recurring structural feature.

5. Buyback-vs-issuance balance. The simultaneous acceleration of buybacks (MetLife, Deutsche Telekom, BASF, ING) and new issuance (biotech IPOs, SPACs, data-center mega-filings) is a tug-of-war for equity capital. Which side absorbs more in the back half of 2026 will shape the liquidity picture for the entire market.